Phase I
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 10, 2020.
It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 7, 2020.
A small biotech company is aiming to recharge tired cells, giving mitochondrial disease patients new hope of a disease-specific treatment.
Several polls have suggested that as much as half of the U.S. population is unlikely to get the vaccine for a variety of reasons, including not feeling it is safe.
According to a warning from federal officials last week, dozens of drug companies, universities and medical device manufacturers owe more than a decade’s worth of data from clinical trials.
The company announced data from Phase I of its Phase I/II placebo-controlled trial of its vaccine with and without Matrix-M adjuvant.
Data security risks are growing as more and more clinical trials embrace telemedicine and other digital technologies.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 5, 2020.
In June, it dosed its first two patients using a novel therapeutic, AMT-130, delivered directly to the brain. Initial readouts are expected in a year’s time.
PRESS RELEASES